Market News
Stay updated with the latest market trends, earnings, and economic indicators.
Aurobindo Pharma clears key US hurdle in Lannett acquisition, closing expected soon
Indian drug giant Aurobindo Pharma is set for a major US expansion. The company has received crucial antitrust clearance from the US Federal Trade Commission for its takeover of Lannett Company. This regulatory approval removes the final hurdle. The acquisition is expected to close by the end of June.
Aurobindo Pharma Clears Major US Regulatory Hurdle In $250 Million Lannett Deal
The Hyderabad-based drugmaker had agreed to acquire Lannett in July 2025 for $250 million as part of its strategy to strengthen its presence in the US generics market.
US FTC imposes divestment condition on Aurobindo Pharma's $250 mn Lannett acquisition
The U.S. Federal Trade Commission (FTC) has mandated that Aurobindo Pharma must sell off four specific drug products. This action is a condition for Aurobindo Pharma to finalize its acquisition of Lannett Company Inc., ensuring no anti-competitive issues arise from the deal.
Aurobindo Pharma Ltd leads losers in 'A' group
Ola Electric Mobility Ltd, Aster DM Healthcare Ltd, Data Patterns (India) Ltd and Shilpa Medicare Ltd are among the other losers in the BSE's 'A' group today, 15 June 2026.
Aurobindo Pharma slides after USFDA classifies Eugia Unit-III as OAI
Aurobindo Pharma shed 1.18% to Rs 1,454.90 after the the United States Food and Drug Administration (USFDA) has classified its Eugia Unit-III manufacturing unit as Official Action Indicated (OAI) following an inspection conducted earlier this year.
Aurobindo Pharma shares fall after USFDA flags Eugia Unit III with OAI status
Aurobindo Pharma said there is no impact on its operations or financials due to the development. The facility can continue to sell the approved drugs, it will not get approvals for new drugs till the violations are addressed to the satisfaction of the regulator.
Stocks to Watch today: RIL, Vedanta, ONGC, Suzlon Energy, Meesho, SEPC
Stock to Watch today, June 15, 2026: NLC India, Aurobindo Pharma, Dr Reddy's Labs, Ashoka Buildcon, JSW Energy, and Ather Energy are among the top stocks to watch during today's trading session
Four Pharma stocks should be on your radar today - Here are their key triggers
An Official Action Indicated (OAI) classification means that significant regulatory violations were found at a facility and the agency is recommending a formal administrative or regulatory action. Aurobindo Pharma will be in focus due to this classification.
Stocks to Watch Today: NLC India, Dr Reddys Labs, Ashoka Buildcon, JSW Energy, Aurobindo Pharma, Power... - Moneycontrol.com
Stocks to Watch Today: NLC India, Dr Reddys Labs, Ashoka Buildcon, JSW Energy, Aurobindo Pharma, Power...Moneycontrol.com
Stocks to Watch for June 15: Vedanta, Aurobindo Pharma, JSW Energy, Dr Reddy's and more
From Vedanta's demerged entities market debut to JSW Energy's wholly owned subsidiary JSW Neo Energy Ltd commissioning the full 150 MW capacity of the Tidong Power Generation Private Ltd hydroelectric project in Himachal Pradesh, here are some stocks to track ahead of Monday's trading session.
Aurobindo Pharma's Eugia Unit-III receives OAI classification from USFDA
Aurobindo Pharma has announced that the United States Food and Drug Administration (USFDA) has classified its Eugia Unit-III manufacturing facility as "Official Action Indicated" (OAI) following an inspection conducted earlier this year.
Aurobindo Pharma unit in Telangana classified "OAI" by US FDA after inspection
Shares of Aurobindo Pharma Ltd ended at ₹1,469.30, up by ₹5.20, or 0.36%, on the BSE.